Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.

Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ.

Circulation. 2006 Jun 20;113(24):2803-9. Epub 2006 Jun 12.

2.

Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.

Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, Guastaroba P, Grilli R, Maresta A.

Circulation. 2007 Jun 26;115(25):3181-8. Epub 2007 Jun 11.

3.

Patterns of use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents.

Ko DT, Chiu M, Guo H, Austin PC, Marquis JF, Tu JV.

Am Heart J. 2009 Oct;158(4):592-598.e1. doi: 10.1016/j.ahj.2009.06.030. Epub 2009 Aug 22.

PMID:
19781419
4.

Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment.

Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E.

Circulation. 2007 Aug 14;116(7):745-54. Epub 2007 Jul 30.

5.

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators.

Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26.

6.

Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation.

Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K; j-Cypher Registry Investigators.

Circulation. 2009 Feb 24;119(7):987-95. doi: 10.1161/CIRCULATIONAHA.108.808311. Epub 2009 Feb 9.

7.

Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.

Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):381-91. doi: 10.1161/CIRCINTERVENTIONS.111.967463. Epub 2012 May 22.

8.

High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.

Migliorini A, Valenti R, Marcucci R, Parodi G, Giuliani G, Buonamici P, Cerisano G, Carrabba N, Gensini GF, Abbate R, Antoniucci D.

Circulation. 2009 Dec 1;120(22):2214-21. doi: 10.1161/CIRCULATIONAHA.109.883454. Epub 2009 Nov 16.

9.

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators.

J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91. Epub 2006 Nov 2.

10.

Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry.

Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, Sangiorgio P, Tarantino F, Geraci G, Castriota F, Tondi S, Saia F, Cooke RM, Guastaroba P, Grilli R, Marzocchi A, Maresta A.

Circulation. 2008 Feb 19;117(7):923-30. doi: 10.1161/CIRCULATIONAHA.107.730416. Epub 2008 Feb 4.

11.

Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.

Whan Lee C, Kim SH, Suh J, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ.

Catheter Cardiovasc Interv. 2008 Apr 1;71(5):594-8. doi: 10.1002/ccd.21399.

PMID:
18311841
12.

Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).

Daemen J, Tanimoto S, García-García HM, Kukreja N, van de Sande M, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW.

Am J Cardiol. 2007 Apr 15;99(8):1027-32. Epub 2007 Mar 6.

PMID:
17437722
13.

Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.

Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP; e-Cypher Investigators.

Circulation. 2006 Mar 21;113(11):1434-41. Epub 2006 Mar 13.

14.

Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction.

Slottow TL, Steinberg DH, Roy P, Javaid A, Buch AN, Okabe T, Xue Z, Smith K, Torguson R, Pichard AD, Satler LF, Suddath WO, Kent KM, Waksman R.

Cardiovasc Revasc Med. 2008 Jan-Mar;9(1):24-8. doi: 10.1016/j.carrev.2007.06.002.

PMID:
18206634
15.

Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.

Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJ; ZEST-AMI Investigators.

Am J Cardiol. 2009 Nov 15;104(10):1370-6. doi: 10.1016/j.amjcard.2009.06.059. Epub 2009 Sep 26.

PMID:
19892052
16.

[Optimal platelet inhibition after coronary stent implantation. Current status].

Silber S, Hoffmeister HM, Bode C.

Herz. 2008 Jun;33(4):244-53. doi: 10.1007/s00059-008-3138-9. Review. German.

PMID:
18581073
17.

Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.

Bertrand OF, Faurie B, Larose E, Nguyen CM, Gleeton O, Déry JP, Noël B, Proulx G, Roy L, Costerousse O, De Larochellière R, Rodés-Cabau J.

J Invasive Cardiol. 2008 Mar;20(3):99-104.

18.

Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings.

Harjai KJ, Orshaw P, Boura J, Sporn D.

Am J Cardiol. 2009 Jun 1;103(11):1537-45. doi: 10.1016/j.amjcard.2009.02.017. Epub 2009 Apr 22.

PMID:
19463512
19.
20.

Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.

Simonton CA, Brodie B, Cheek B, Krainin F, Metzger C, Hermiller J, Juk S, Duffy P, Humphrey A, Nussbaum M, Laurent S; STENT Group.

J Am Coll Cardiol. 2007 Sep 25;50(13):1214-22. Epub 2007 Sep 10.

Supplemental Content

Support Center